Abivax (ABVX) Non-Current Deferred Tax Liability (2023 - 2026)
Abivax (ABVX) posted quarterly Non-Current Deferred Tax Liability of $7.1 million for Q1 2026, up 4.5% quarter-over-quarter from $6.8 million in Q4 2025.
Abivax (ABVX) Non-Current Deferred Tax Liability (2023 - 2026) Analysis & Trends
Abivax's Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $7.1 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (changed N/A YoY), while the FY2025 annual figure was $6.8 million, up 302.17% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $7.1 million, up from $6.8 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $7.1 million in Q1 2026, with the low at $477717.3 in Q4 2023.
- The 4-year median for Non-Current Deferred Tax Liability is $4.2 million (2024), against an average of $4.0 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability surged 254.32% in 2024, then surged 302.17% in 2025.
- Abivax's Non-Current Deferred Tax Liability stood at $477717.3 in 2023, then surged by 254.32% to $1.7 million in 2024, then soared by 302.17% to $6.8 million in 2025, then grew by 4.5% to $7.1 million in 2026.
- Business Quant data shows ABVX's Non-Current Deferred Tax Liability at $7.1 million in Q1 2026, $6.8 million in Q4 2025, and $1.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.11 Mn |
| Mar 31, 2026 | 7.11 Mn |
| Dec 31, 2025 | 6.81 Mn |
| Dec 31, 2025 | 6.81 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | 477,717.32 |
| Dec 31, 2023 | 477,717.32 |